HBV Clinical Trial
Official title:
Effectiveness and Safety of Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant With HBV-related Disease
TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant.
LT has evolved rapidly, becoming the standard therapy for acute and chronic liver failure of a variety of aetiologies, with more than 80,000 procedures performed to date [13]. HBV infection is a worldwide public health problem, especially in China. The need for an antiviral treatment with NAs for liver transplant recipients has two objectives: the improvement of liver function and to decrease the risk of HBV recurrence after transplant. TAF, TDF and ETV are currently the first-line therapy in patients with CHB in all CHB treatment guidelines, which have a greater potency and higher barriers to resistance. TAF treatment for HBV prophylaxis could lead to significant reduction in ALT and significant improvement in renal function. However, data are scarce regarding to TAF monotherapy without HBIG for HBV prophylaxis in post orthotopic liver transplant with HBV-related disease. This study is based on a real-world, multi-center, prospective study to assess the effectiveness and safety of TAF for HBV prophylaxis, which will fill in gaps with TAF monotherapy without HBIG in post liver transplant. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05442437 -
Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV
|
Early Phase 1 | |
Completed |
NCT04519710 -
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies
|
N/A | |
Recruiting |
NCT04562051 -
Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
|
||
Recruiting |
NCT04683341 -
Tenofovir Alafenamide in HBV Related Decompensated Liver
|
Phase 4 | |
Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
Completed |
NCT02044068 -
Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women
|
N/A | |
Completed |
NCT03239353 -
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04904835 -
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
|
||
Terminated |
NCT04059198 -
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
|
Phase 2 | |
Not yet recruiting |
NCT05293158 -
Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study
|
N/A | |
Not yet recruiting |
NCT05028322 -
Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen
|
Phase 2 | |
Completed |
NCT02312531 -
Prevention for Mother-to-infant Transmission of HBV
|
N/A | |
Not yet recruiting |
NCT01556815 -
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
Recruiting |
NCT05951751 -
The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)
|
N/A | |
Not yet recruiting |
NCT06307808 -
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
|
||
Completed |
NCT03149627 -
Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
|
||
Recruiting |
NCT04886336 -
The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
|
||
Recruiting |
NCT04568265 -
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
|
Phase 2 | |
Terminated |
NCT02826018 -
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
|
Phase 1 |